Development of a Pharmacy-based Comorbidity Index for Patients With Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Medical Care

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MLR.0000000000000149PMID 24926705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival

  2016cited by this paper
• Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices.

  2014cited by this paper
• Incidence and management of hepatocellular carcinoma among Māori and non‐Māori New Zealanders

  2013cited by this paper
• Ethnicity and rectal cancer management in New Zealand.

  2013cited by this paper
• Review of methods used to measure comorbidity in cancer populations: no gold standard exists.

  2012influential reference
• Accuracy of hospital morbidity data and the performance of comorbidity scores as predictors of mortality.

  2012cited by this paper
• Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting.

  2011influential reference
• Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.

  2011cited by this paper
• Validity of the Medication-Based Disease Burden Index Compared with the Charlson Comorbidity Index and the Cumulative Illness Rating Scale for Geriatrics

  2011cited by this paper
• Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

  2010cited by this paper
• How well does routine hospitalisation data capture information on comorbidity in New Zealand?

  2010cited by this paper
• Validity of medication‐based co‐morbidity indices in the Australian elderly population

  2009cited by this paper
• The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study

  2009cited by this paper
• Rates and predictors of chemotherapy use for stage III colon cancer

  2008cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• Interaction between comorbidity and cancer.

  2007cited by this paper
• Comorbidity: The Ultimate Geriatric Syndrome Introduction and Summary Report of the National Institute on Aging Task Force on Comorbidity

  2007cited by this paper
• Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent

  2006cited by this paper
• Adapting the Rx-Risk-V for Mortality Prediction in Outpatient Populations

  2006cited by this paper
• Comparison of risk adjustment measures based on self-report, administrative data, and pharmacy records to predict clinical outcomes

  2006cited by this paper
• Development and Validation of the Medication-Based Disease Burden Index

  2006cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Prevalence of Multimorbidity Among Adults Seen in Family Practice

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data

  2005cited by this paper
• A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

  2005cited by this paper
• Co‐morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer

  2005cited by this paper
• Comorbidity as a Predictor of Stage of Illness for Patients With Breast Cancer

  2005cited by this paper
• Comorbidity: implications for research and practice in geriatric oncology.

  2003cited by this paper
• Construction and Characteristics of the RxRisk-V: A VA-Adapted Pharmacy-Based Case-mix Instrument

  2003cited by this paper
• Impact of comorbidity on lung cancer survival

  2003cited by this paper
• Predicting Costs of Care Using a Pharmacy-Based Measure Risk Adjustment in a Veteran Population

  2003cited by this paper
• Risk Adjustment Using Automated Ambulatory Pharmacy Data: The RxRisk Model

  2003cited by this paper
• Development of a new head and neck cancer-specific comorbidity index.

  2002cited by this paper
• Measuring Comorbidity in Patients With Head and Neck Cancer

  2002cited by this paper
• Causes and consequences of comorbidity: a review.

  2001cited by this paper
• Measurement and impact of comorbidity in older cancer patients.

  2000cited by this paper
• Development of a comorbidity index using physician claims data.

  2000cited by this paper
• A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer.

  1999cited by this paper
• Comorbidity measures for use with administrative data.

  1998cited by this paper
• Administrative data. Baby or bathwater?

  1998cited by this paper
• Assessing Quality Using Administrative Data

  1997cited by this paper
• Aging, comorbidity, and breast cancer survival: an epidemiologic view.

  1993cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper
• THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE.

  1970cited by this paper

• Behavioral Responses to Healthcare Funding Decisions and Their Impact on Value for Money: Evidence From Australia

  2025cites this paper
• Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study

  2025cites this paper
• Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

  2024cites this paper
• Prevalence of drugs used for chronic conditions after diagnosis of thyroid cancer: A register-based cohort study.

  2024cites this paper
• DAta Linkage to Enhance Cancer Care (DaLECC): Protocol of a Large Australian Data Linkage Study

  2023influential citation
• Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer.

  2023cites this paper
• Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study

  2023cites this paper
• Occurrence of comorbidity with colorectal cancer and variations by age and stage at diagnosis.

  2022cites this paper
• Prescribed drugs in 27 000 individuals after diagnosis of colorectal cancer: A population‐based cohort study

  2021cites this paper
• The impact of timely cancer diagnosis on age disparities in colon cancer survival.

  2021cites this paper
• More than two-dozen Prescription Drug-Based Risk SCORES are available for risk adjustment: A Systematic Review.

  2021cites this paper
• Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients

  2021cites this paper
• The impact of timely cancer diagnosis on age disparities in colon cancer survival in New Zealand

  2020cites this paper
• Comorbidity in Aging and Cancer

  2020cites this paper
• The burden of chronic diseases among Australian cancer patients: Evidence from a longitudinal exploration, 2007-2017

  2020cites this paper
• Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review

  2020cites this paper
• Comparison between drug therapy-based comorbidity indices and the Charlson Comorbidity Index for the detection of severe multimorbidity in older subjects

  2020cites this paper
• Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors

  2020cites this paper
• A Pharmaceutical Dispensing–based Index of Mortality Risk From Long-term Conditions Performed as well as Hospital Record–based Indices

  2019cites this paper
• The Comorbidities Coma Scale (CoCoS): Psychometric Properties and Clinical Usefulness in Patients With Disorders of Consciousness

  2019cites this paper
• Adapting the Elixhauser comorbidity index for cancer patients

  2018cites this paper
• The impact of comorbidity on the survival and supportive care needs of Aboriginal and Torres Strait Islander Australians diagnosed with cancer

  2018cites this paper
• Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.

  2018cites this paper
• Development and validation of a Medicines Comorbidity Index for older people

  2017influential citation
• Evaluation of the National Minimum Data Set for Neurological Conditions in Older Adults

  2017cites this paper
• Comorbidity assessment in localized prostate cancer: a systematic review protocol.

  2017cites this paper
• Quality Indicators for the management of lung cancer

  2016cites this paper
• How Do We Measure Comorbidity

  2016cites this paper
• The Benefit and Tolerability of Adjuvant Chemotherapy in Elderly Stage III Colon Cancer Patients: A 3 Year Retrospective Audit

  2016cites this paper
• The impact of comorbidity on cancer and its treatment

  2016cites this paper
• Modification of claims-based measures improves identification of comorbidities in non-elderly women undergoing mastectomy for breast cancer: a retrospective cohort study

  2016cites this paper
• Risk of Cancer in Patients with Insomnia, Parasomnia, and Obstructive Sleep Apnea: A Nationwide Nested Case-Control Study

  2015cites this paper
• Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls

  2015cites this paper